Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2026The American Journal of Gastroenterology

The Costs of Inflammatory Bowel Disease and the Financial Impact of Insurance Delays

View Full Paper
Ask AI
Bookmark
Share

Authors

SBShubha P. BhatCleveland ClinicTFTolulope FalaiyeChildren's Hospital ColoradoJMJ MosesUniversity of Calabar

Discussion

Loading...

Member takes

Implication

Review assesses costs of inflammatory bowel disease and impacts of insurance delays, indicating need for streamlined processes.

Key Points

  • This review aims to summarize costs associated with inflammatory bowel disease and explore the impact of prior authorization delays.
  • Reviewed literature on costs related to inflammatory bowel disease.
  • Analyzed the administrative processes influencing treatment access.
  • Identified strategies to mitigate costs in IBD management.
  • Highlight the substantial costs tied to advanced therapies for IBD.
  • Show that insurance delays lead to negative clinical outcomes and higher absenteeism.
  • Discuss the impact of non-standardized prior authorization processes on treatment access.

Cite This Study

Bhat et al. (2026) studied this question.

synapsesocial.com/papers/69a3d89aec16d51705d2f9b5https://doi.org/10.14309/ajg.0000000000003975
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial2024 · 307 citations
  2. 2Insurance Companies' Poor Adherence to Guidelines for Moderate-to-Severe Ulcerative Colitis/Crohn's Disease Management2024 · 13 citations
  3. 3Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease2024 · 195 citations